AstraZeneca’s Triple Regulatory Wins For Enhertu, Tezspire And Ultomiris Herald Sales Boost

Across US And EU

 
• By Ayisha Sharma

The major has won US priority review for a commercially crucial label expansion of its breast cancer drug Enhertu while Tezspire and Ultomiris attracted positive CHMP opinions across the Atlantic.    

Dartboard with three arrows on bullseye target
The Three Regulatory Successes Mean Bigger Markets • Source: Shutterstock

More from Business

More from Scrip